Asenapine vs Paliperidone palmitate (Invega Trinza)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Asenapine

Marketed by AbbVie and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00212784 · Phase 3 · completed

This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.

Reported efficacy

Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)

Result source: NCT00212771

Paliperidone palmitate (Invega Trinza)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule (palmitate ester prodrug, long-acting injectable suspension)
Weak signal

NCT02713282 · Phase 3 · completed

This was a single-group, open-label study without randomization or a comparator arm, so it could not directly compare the 3-month formulation with placebo or another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)

Result source: NCT04072575

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsenapinePaliperidone palmitate (Invega Trinza)
PANSS total, change-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
-1.8 vs -1.6vs PP3Mwk 52 · n 473NCT03345342
CGI-S, change-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
0 vs 0vs PP3Mwk 52 · n 475NCT03345342
2 other results
PANSS response39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
—Not posted · NCT02713282
PSP, change—Not posted · NCT002127711 vs 1.1vs PP3Mwk 52 · n 473NCT03345342
2 other results
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
Relapse (% of patients)—Not posted · NCT00212771—Not posted · NCT02713282

PANSS total, change

Asenapine
-25.5 vs -17.8−7.7 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
18 other results
  • -21.7 vs -16.2 5 mg BID · wk 6 · n 111 · Phase 3 · primary NCT01617187
  • -12.2 vs -0.9 5 mg BID · wk 6 · n 173 · Phase 3 · primary NCT01098110
  • -14.2 vs -0.9 10 mg BID · wk 6 · n 178 · Phase 3 · primary NCT01098110
  • -23.7 vs -17.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · primary NCT01190254
  • -17.4 vs -16.2 2.5 mg BID · wk 6 · n 96 · Phase 3 · primary NCT01617187
  • -19 vs -15.4 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -17.1 vs -15.5 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -14.8 vs -13.2 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -12.5 vs -10.7 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -9.1 vs -7.1 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -4.9 vs -4.8 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -17 vs -15.4 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -12.3 vs -15.5 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -12 vs -13.2 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -9.9 vs -10.7 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -7.2 vs -7.1 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -4 vs -4.8 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
  • -21 vs -27.5 wk 52 · Phase 3 · primary NCT00212784
Paliperidone palmitate (Invega Trinza)
-1.8 vs -1.6vs PP3Mwk 52 · n 473NCT03345342

CGI-S, change

Asenapine
-1.3 vs -0.8−0.5 vs placebo5.0 mg BID · wk 8 · n 79NCT01190254
17 other results
  • -1.2 vs -1 5 mg BID · wk 6 · n 111 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.2 5 mg BID · wk 6 · n 173 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 5 mg BID · wk 5 · n 111 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 5 mg BID · wk 4 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.7 5 mg BID · wk 3 · n 111 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 5 mg BID · wk 2 · n 111 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 5 mg BID · wk 1 · n 111 · Phase 3 · secondary NCT01617187
  • -0.2 vs -0.2 5 mg BID · wk 0.57 · n 111 · Phase 3 · secondary NCT01617187
  • -0.8 vs -0.2 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
  • -1.1 vs -0.8 2.5 mg BID · wk 8 · n 72 · Phase 3 · secondary NCT01190254
  • -0.9 vs -1 2.5 mg BID · wk 6 · n 96 · Phase 3 · secondary NCT01617187
  • -0.9 vs -0.8 2.5 mg BID · wk 5 · n 96 · Phase 3 · secondary NCT01617187
  • -0.7 vs -0.8 2.5 mg BID · wk 4 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.7 2.5 mg BID · wk 3 · n 96 · Phase 3 · secondary NCT01617187
  • -0.6 vs -0.5 2.5 mg BID · wk 2 · n 96 · Phase 3 · secondary NCT01617187
  • -0.3 vs -0.3 2.5 mg BID · wk 1 · n 96 · Phase 3 · secondary NCT01617187
  • -0.1 vs -0.2 2.5 mg BID · wk 0.57 · n 96 · Phase 3 · secondary NCT01617187
Paliperidone palmitate (Invega Trinza)
0 vs 0vs PP3Mwk 52 · n 475NCT03345342
2 other results

PANSS response

Asenapine
39.3% vs 20.7%+18.6 vs placebo5 mg BID · wk 6 · n 173NCT01098110
1 other result
  • 43.8% vs 20.7% 10 mg BID · wk 6 · n 178 · Phase 3 · secondary NCT01098110
Paliperidone palmitate (Invega Trinza)
—Not posted · NCT02713282

PSP, change

Asenapine
—Not posted · NCT00212771
Paliperidone palmitate (Invega Trinza)
1 vs 1.1vs PP3Mwk 52 · n 473NCT03345342
2 other results
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702

Relapse (% of patients)

Asenapine
—Not posted · NCT00212771
Paliperidone palmitate (Invega Trinza)
—Not posted · NCT02713282
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Asenapine: 5 of 5 rows · Paliperidone palmitate (Invega Trinza): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAsenapine
Rows use multiple source trials
Paliperidone palmitate (Invega Trinza)
Rows use multiple source trials
PANSS Total
absolute change · score
No placebo or comparator arm
-11.08 score @ 52wka,b,c
NCT01244828 · Phase 3 · registry result, not featured evidence
show 1 more dose
-5.48 score
NCT01244828 · Phase 3 · registry result, not featured evidence
0.7 score @ 104wk700 or 1000 mg eqb,c
NCT04072575 · Phase 3 · combination
Dropout rate
44.4%5 mg twice dailyd
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
16.7%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
54.8%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
1%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
35.2%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
40.1%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
50%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.9%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
20.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
17.3%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
33.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
50.4%
NCT00145496 · Phase 3 · registry result, not featured evidence
30.4%
NCT00150176 · Phase 3 · registry result, not featured evidence
15.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
67.7%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
33.3%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
25%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—Double-blind PP6Me
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
13.5%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
—
NCT01529515 · Phase 3
—Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
22.2%5 mg twice dailyd
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
22.3%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
0%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
23.6%
NCT01244828 · Phase 3 · registry result, not featured evidence
17%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
17.6%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
0%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
5.1%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
7.5%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
6.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
8.1%
NCT00174265 · Phase 3 · registry result, not featured evidence
17.2%
NCT00145496 · Phase 3 · registry result, not featured evidence
8.2%
NCT00150176 · Phase 3 · registry result, not featured evidence
7.5%
NCT00265343 · Phase 3 · registry result, not featured evidence
11.8%
NCT00156065 · Phase 3 · registry result, not featured evidence
—5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—Double-blind PP6Me
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
3.9%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
—
NCT01529515 · Phase 3
—Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Serious AEs
0%5 mg twice dailyd
NCT01549041 · Phase 4 · registry result, not featured evidence
show 23 more results
0%10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
20.4%5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence
4.4%5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2%2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.9%
NCT01244828 · Phase 3 · registry result, not featured evidence
5.7%5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
2.8%10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
12.5%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
3.6%Asenapine - Participants Who Were
NCT01190267 · Phase 3 · registry result, not featured evidence
2.8%5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
3.1%2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
4.7%
NCT00174265 · Phase 3 · registry result, not featured evidence
12.3%
NCT00145496 · Phase 3 · registry result, not featured evidence
3.1%
NCT00150176 · Phase 3 · registry result, not featured evidence
6.7%
NCT00265343 · Phase 3 · registry result, not featured evidence
14.1%
NCT00156065 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT01206517 · Phase 1 · registry result, not featured evidence
5%Double-blind PP6Me
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
5.5%Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
4.5%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
2.5%
NCT01529515 · Phase 3
12.8%Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
5.3%Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
2%Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
5 mg twice dailyd
daytime drowsiness 22.2%
NCT01549041 · Phase 4 · registry result, not featured evidence
show 19 more results
10 mg daily in the evening
daytime drowsiness 0%
NCT01549041 · Phase 4 · registry result, not featured evidence
5/10 mg BID
nasopharyngitis 21.7%
schizophrenia 10.8%
somnolence 10.8%
NCT01142596 · Phase 3 · registry result, not featured evidence
5 mg BID
insomnia 15% (placebo 13.9%)
headache 8.8% (placebo 2%)
anxiety 7.1% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
2.5 mg BID
headache 10.3% (placebo 2%)
insomnia 9.3% (placebo 13.9%)
anxiety 7.2% (placebo 11.9%)
NCT01617187 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21%
somnolence 12.7%
weight increased 12.7%
NCT01244828 · Phase 3 · registry result, not featured evidence
5 mg BID
akathisia 11.4% (placebo 5.2%)
hypoaesthesia oral 10.9% (placebo 3.4%)
insomnia 9.7% (placebo 12.1%)
NCT01098110 · Phase 3 · registry result, not featured evidence
10 mg BID
schizophrenia 13.8% (placebo 24.1%)
somnolence 12.2% (placebo 1.7%)
akathisia 10.5% (placebo 5.2%)
NCT01098110 · Phase 3 · registry result, not featured evidence
accidental overdose 12.5%
acne 12.5%
akathisia 12.5%
NCT01190267 · Phase 3 · registry result, not featured evidence
somnolence 14.8%
headache 6.6%
sedation 5.1%
NCT01190267 · Phase 3 · registry result, not featured evidence
5.0 mg BID
somnolence 17% (placebo 6.9%)
sedation 11.3% (placebo 2%)
insomnia 9.4% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
2.5 mg BID
somnolence 20.4% (placebo 6.9%)
dizziness 7.1% (placebo 1%)
headache 7.1% (placebo 5.9%)
NCT01190254 · Phase 3 · registry result, not featured evidence
insomnia 10.6%
weight increased 5.9%
headache 2.4%
NCT00174265 · Phase 3 · registry result, not featured evidence
insomnia 17.6%
somnolence 14.8%
headache 13.5%
NCT00145496 · Phase 3 · registry result, not featured evidence
insomnia 20.1% (placebo 24.5%)
somnolence 16% (placebo 17.2%)
weight increased 14.4% (placebo 10.9%)
NCT00150176 · Phase 3 · registry result, not featured evidence
headache 5.2%
influenza 5.2%
schizophrenia 5.2%
NCT00265343 · Phase 3 · registry result, not featured evidence
insomnia 18.5%
headache 10.9%
parkinsonism 10.9%
NCT00156065 · Phase 3 · registry result, not featured evidence
5 mg
dystonia 66.7%
dizziness 33.3%
nausea 33.3%
NCT01206517 · Phase 1 · registry result, not featured evidence
10 mg
hypoaesthesia oral 50%
dizziness 38.9%
dysgeusia 38.9%
NCT01206517 · Phase 1 · registry result, not featured evidence
2.5 mg
sedation 33.3%
dysgeusia 16.7%
hypoaesthesia oral 16.7%
NCT01206517 · Phase 1 · registry result, not featured evidence
e
weight increased 8.4%
injection site pain 7.7%
headache 6.7%
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
nasopharyngitis 3.7%
upper respiratory tract infection 0.9%
headache 0%
NCT03345342 · Phase 3 · Schizophrenia · phase 3
700 or 1000 mg eq
headache 13.5%
blood prolactin increased 10.7%
hyperprolactinaemia 7.3%
NCT04072575 · Phase 3 · combination
headache 8.8% (placebo 4.1%)
weight increased 8.8% (placebo 3.4%)
anxiety 8.1% (placebo 10.3%)
NCT01529515 · Phase 3
weight increased 28.2%
akathisia 9%
headache 9%
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
weight increased 15.8%
anxiety 10.5%
insomnia 10.5%
NCT02431702 · Phase 3 · registry result, not featured evidence
weight increased 14.3%
insomnia 10.2%
nasopharyngitis 6.1%
NCT02431702 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dPopulation comparability has not been reviewed for these studies.
  5. ePopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Asenapine

BPRS Total 7.72 score @ 2wk5 mg twice daily
absolute change · score
No placebo or comparator arm
NCT01549041 · Phase 4 · registry result, not featured evidence
show 1 more result
16.08 score @ 2wk10 mg daily in the evening
NCT01549041 · Phase 4 · registry result, not featured evidence
Time to Loss of Efficacy 5.82 months5/10 mg BID
time to event · months
Extension (open-label)
No placebo or comparator arm
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 177 days as posted
show 1 more result
12.09 months*5/10 mg BID
NCT01142596 · Phase 3 · registry result, not featured evidence · converted to months from 368 days as posted
PANSS 30% 25.2% (n=111) vs 19.2% (n=99) placebo @ 6wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
0% (n=111) vs 2.1% (n=99) placebo @ 0.57wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 5.1% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.4% (n=111) vs 7.1% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
14.4% (n=111) vs 13.1% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
16.2% (n=111) vs 14.1% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
21.6% (n=111) vs 17.2% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
49% (n=104) vs 36% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 51 participants as posted
72.1% (n=104) vs 62% (n=100) placebo @ 8.4wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
14.6% (n=96) vs 19.2% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0% (n=96) vs 2.1% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
2.1% (n=96) vs 5.1% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
5.2% (n=96) vs 7.1% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
8.3% (n=96) vs 13.1% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
10.4% (n=96) vs 14.1% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
15.6% (n=96) vs 17.2% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
50% (n=96) vs 36% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 48 participants as posted
64.2% (n=96) vs 62% (n=100) placebo @ 8.4wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
Weight 1.3 vs 0.3 placebo kg @ 6wk5 mg BID
absolute change · kg
NCT01617187 · Phase 3 · registry result, not featured evidence
show 2 more results
1.3 vs 0.3 placebo kg @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
0 vs 2.6 Olanzapine kg @ 26wk
NCT00145496 · Phase 3 · registry result, not featured evidence
CGI-I 33.3% (n=111) vs 37.8% (n=99) placebo @ 0.57wk5 mg BID
responder rate · % of participants
NCT01617187 · Phase 3 · registry result, not featured evidence
show 19 more results
46.8% (n=111) vs 45.5% (n=99) placebo @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=111) vs 54.5% (n=99) placebo @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.1% (n=111) vs 58.6% (n=99) placebo @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
62.2% (n=111) vs 60.6% (n=99) placebo @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
64% (n=111) vs 64.6% (n=99) placebo @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
66.7% (n=111) vs 62.6% (n=99) placebo @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
63.6% (n=173) vs 41.4% (n=174) placebo @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
39.4% (n=104) vs 28% (n=100) placebo @ 8wk*5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 41 participants as posted
60.1% (n=104) vs 54.7% (n=100) placebo @ 8.3wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
70.2% (n=178) vs 41.4% (n=174) placebo @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
34.7% (n=96) vs 37.8% (n=99) placebo @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 45.5% (n=99) placebo @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
51% (n=96) vs 54.5% (n=99) placebo @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
54.2% (n=96) vs 58.6% (n=99) placebo @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
58.3% (n=96) vs 60.6% (n=99) placebo @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
60.4% (n=96) vs 64.6% (n=99) placebo @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
59.4% (n=96) vs 62.6% (n=99) placebo @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
37.5% (n=96) vs 28% (n=100) placebo @ 8wk*2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence · converted to % from 36 participants as posted
47.1% (n=96) vs 54.7% (n=100) placebo @ 8.3wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Negative -0.5 vs -0.8 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-1.3 vs -1.1 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -1.8 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.3 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -3 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -2.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.72 vs -0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.27 vs -0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.1 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.6 vs -1.8 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.3 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -3 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.3 vs -3.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS Positive -1.6 vs -1.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 15 more results
-2.8 vs -2.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3.7 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5 vs -4.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.7 vs -5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.5 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.2 vs -5.4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.31 vs -0.85 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.63 vs -0.85 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -1.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -3.7 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.1 vs -5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -5.5 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.6 vs -5.4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -2.7 vs -2.4 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-4.9 vs -3.6 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.2 vs -5.4 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.4 vs -6.7 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.2 vs -7.7 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-9.2 vs -7.6 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.1 vs -8 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.26 vs 0.19 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-11.5 vs -8.5 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-6.34 vs 0.19 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-2.2 vs -2.4 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.6 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.1 vs -5.4 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -6.7 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.9 vs -7.7 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.8 vs -7.6 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-8.9 vs -8 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-10.9 vs -8.5 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -1.8 vs -2 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-2.9 vs -2.8 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4 vs -4.1 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.4 vs -5.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.3 vs -5.6 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.7 vs -6.1 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.6 vs -6.2 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.78 vs -1.37 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-8.9 vs -6.1 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-5.03 vs -1.37 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.3 vs -2 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.8 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -4.1 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.5 vs -5.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.8 vs -5.6 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.1 vs -6.1 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-6.8 vs -6.2 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-7.9 vs -6.1 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative -0.8 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.9 vs -1.3 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.8 vs -2 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.2 vs -2.5 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -3.5 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.9 vs -3 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.7 vs -4 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.77 vs -0.41 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-5.3 vs -3.7 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-3.35 vs -0.41 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.7 vs -1.3 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -2 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.6 vs -2.5 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.9 vs -3.5 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -3 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.4 vs -4 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-5.2 vs -3.7 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought -0.7 vs -0.7 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-1.4 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2 vs -1.5 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.1 vs -2.4 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -2.7 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.48 vs 0.24 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-4.8 vs -3.4 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-2.85 vs 0.24 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.7 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.3 vs -1.5 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.3 vs -2.1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-2.4 vs -2.4 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.7 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-4.3 vs -3.4 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.3 vs -0.5 placebo score @ 0.57wk5 mg BID
absolute change · score
NCT01617187 · Phase 3 · registry result, not featured evidence
show 17 more results
-0.5 vs -0.7 placebo score @ 1wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.9 placebo score @ 2wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -1 placebo score @ 3wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -1 placebo score @ 4wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.5 vs -1.4 placebo score @ 5wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.8 vs -1.1 placebo score @ 6wk5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.77 vs 0.86 placebo score @ 6wk5 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.8 placebo score @ 8wk5.0 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence
-1.4 vs 0.86 placebo score @ 6wk10 mg BID
NCT01098110 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.5 placebo score @ 0.57wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.7 placebo score @ 1wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.9 placebo score @ 2wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.8 vs -1 placebo score @ 3wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-0.5 vs -1 placebo score @ 4wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.4 vs -1.4 placebo score @ 5wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-1.1 vs -1.1 placebo score @ 6wk2.5 mg BID
NCT01617187 · Phase 3 · registry result, not featured evidence
-3.8 vs -2.8 placebo score @ 8wk2.5 mg BID
NCT01190254 · Phase 3 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

Paliperidone palmitate (Invega Trinza)

Time to Relapse NA vs NA PP3M months @ 52wk
time to event · months
NCT03345342 · Phase 3 · Schizophrenia · phase 3
PSP 1 vs 1.1 PP3M score @ 52wk
absolute change · score
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 2 more results
2.5 vs 2.9 Oral Antipsychotics score @ 39.1wk
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 7 Oral Antipsychotics score @ 78.2wk
NCT02431702 · Phase 3 · registry result, not featured evidence
Symptomatic Remission 66.3% (n=478) vs 70.1% (n=224) PP3M @ 52wk
responder rate · % of participants
NCT03345342 · Phase 3 · Schizophrenia · phase 3
Relapse 3.9% (n=178) @ 104wk700 or 1000 mg eq
event count · % of participants
No placebo or comparator arm
NCT04072575 · Phase 3 · combination · converted to % from 7 Participants as posted
CGI-S 0 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
PSP 0.5 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
Time to Relapse Median NA vs 12.98 placebo months @ 60wk
time to event · months
NCT01529515 · Phase 3
PANSS Total -0.5 vs 6.7 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3
CGI-S 0.1 vs 0.4 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3
PSP -0.5 vs -4.2 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3
Time to Treatment Failure NA vs NA Oral Antipsychotics months
time to event · months
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
NA vs NA Oral Antipsychotics months
NCT02431702 · Phase 3 · registry result, not featured evidence
MCCB Composite 1.6 vs 3.2 Oral Antipsychotics T-score @ 78.2wk
absolute change · T-score
NCT02431702 · Phase 3 · registry result, not featured evidence
show 3 more results
-0.7 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3 · registry result, not featured evidence
-0.2 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3 · registry result, not featured evidence
2 vs 2.8 Oral Antipsychotics T-score @ 39.1wk
NCT02431702 · Phase 3 · registry result, not featured evidence · combination

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Paliperidone palmitate (Invega Trinza)'s landscape